Profile data is unavailable for this security.
About the company
Mesoblast Limited is an Australia-based is developing a range of late-stage product candidates derived from its proprietary mesenchymal lineage cell therapy technology platforms. The Company’s Remestemcel-L is mesenchymal lineage stromal cell product platform and is in late-stage development for treatment of systemic inflammatory diseases, including Pediatric steroid refractory acute Graft versus Host Disease (SR-aGVHD), acute respiratory distress syndrome (ARDS) and Biologic refractory inflammatory bowel disease. Its Rexlemestrocel-L is mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of advanced chronic heart failure (CHF) and chronic low back pain (CLBP) due to degenerative disc disease. Two products are commercialized in Japan and Europe by the Company’s licensees, and it has a commercial partnership in Europe and China for certain Phase III assets.
- Revenue in AUD (TTM)11.60m
- Net income in AUD-113.55m
- Incorporated2004
- Employees83.00
- LocationMesoblast LtdL 38 55 Collins StMELBOURNE 3000AustraliaAUS
- Phone+61 39639-6036
- Fax+61 39639-6030
- Websitehttps://www.mesoblast.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cogstate Ltd | 64.53m | 8.57m | 222.85m | 61.00 | 28.34 | 3.78 | 17.35 | 3.45 | 0.0459 | 0.0459 | 0.3497 | 0.3442 | 0.7757 | -- | 5.58 | -- | 10.30 | 6.01 | 13.84 | 9.22 | 54.69 | 51.50 | 13.28 | 7.26 | -- | -- | 0.0135 | 0.00 | -8.62 | 7.25 | -52.56 | -- | -5.06 | -- |
| Race Oncology Ltd | 885.59k | -11.17m | 230.41m | -- | -- | 11.12 | -- | 260.18 | -0.069 | -0.069 | 0.0055 | 0.125 | 0.0336 | -- | 0.326 | -- | -42.44 | -43.50 | -43.67 | -45.25 | -- | -- | -1,261.86 | -5,058.82 | -- | -- | 0.00 | -- | 997.63 | 93.78 | 11.41 | -- | -- | -- |
| Probiotec Ltd | 221.22m | 8.69m | 231.77m | 111.00 | 27.45 | 2.62 | 9.68 | 1.05 | 0.1038 | 0.1038 | 2.64 | 1.09 | 0.9483 | 7.03 | 6.99 | -- | 3.72 | 4.58 | 5.36 | 5.94 | 29.95 | 30.21 | 3.93 | 5.73 | 1.09 | 3.33 | 0.4937 | 47.90 | 17.39 | 23.10 | -19.61 | 20.84 | 12.97 | 18.77 |
| Botanix Pharmaceuticals Ltd | 200.38k | -10.02m | 354.41m | 1.00 | -- | 7.67 | -- | 1,768.67 | -0.0072 | -0.0072 | 0.0002 | 0.0293 | 0.0059 | -- | 1.09 | -- | -29.28 | -67.71 | -32.25 | -81.15 | -- | -- | -5,002.57 | -8,798.51 | 8.14 | -138.17 | 0.00 | -- | 351.94 | -6.25 | 30.50 | -- | -- | -- |
| Immutep Ltd | 256.62k | -40.50m | 416.09m | 19.00 | -- | 3.60 | -- | 1,621.43 | -0.0394 | -0.0394 | 0.0003 | 0.0973 | 0.0025 | -- | 2.48 | -- | -38.61 | -36.31 | -41.57 | -39.21 | -- | -- | -15,782.59 | -919.13 | -- | -- | 0.0138 | -- | -24.64 | -51.34 | -23.86 | -- | 47.40 | -- |
| Opthea Ltd | 182.00k | -251.18m | 417.57m | 5.00 | -- | -- | -- | 2,294.32 | -0.4814 | -0.4814 | 0.0004 | -0.11 | 0.0007 | -- | 0.1772 | -- | -100.84 | -90.04 | -116.05 | -100.93 | -99.74 | -197.19 | -138,008.10 | -69,641.71 | -- | -29.64 | 1.35 | -- | 19.55 | -34.31 | -53.55 | -- | -3.82 | -- |
| PYC Therapeutics Ltd | 21.54m | -21.65m | 424.84m | 23.00 | -- | 11.86 | -- | 19.72 | -0.006 | -0.006 | 0.0062 | 0.008 | 0.6034 | -- | 2.48 | -- | -60.70 | -41.67 | -81.23 | -46.95 | -- | -- | -100.60 | -178.69 | -- | -50.32 | 0.0174 | -- | -1.11 | 218.52 | -64.39 | -- | 18.46 | -- |
| Imugene Ltd | 0.00 | -89.24m | 570.95m | 0.00 | -- | 2.87 | -- | -- | -0.0132 | -0.0132 | 0.00 | 0.0272 | 0.00 | -- | -- | -- | -40.29 | -26.64 | -43.53 | -28.00 | -- | -- | -- | -- | -- | -- | 0.021 | -- | -- | -- | -0.1207 | -- | -- | -- |
| Mayne Pharma Group Ltd | 278.45m | -258.82m | 574.25m | 900.00 | -- | 1.00 | -- | 2.06 | -3.18 | -2.99 | 3.43 | 6.74 | 0.2105 | 0.8192 | 1.37 | -- | -19.56 | -14.47 | -26.66 | -18.05 | 68.05 | 50.60 | -92.95 | -64.69 | 1.30 | -5.68 | 0.0626 | -- | 20.75 | -18.54 | -51.49 | -- | 18.41 | -- |
| Clinuvel Pharmaceuticals Limited | 87.29m | 30.15m | 766.45m | 16.00 | 26.25 | 4.29 | 24.61 | 8.78 | 0.5825 | 0.5825 | 1.69 | 3.56 | 0.4693 | -0.9514 | 7.35 | -- | 16.21 | 21.25 | 18.57 | 23.55 | 109.28 | -- | 34.54 | 41.84 | 6.43 | 14.53 | 0.006 | 7.44 | 24.27 | 26.14 | 46.58 | 18.27 | 68.74 | 20.11 |
| Clarity Pharmaceuticals Ltd | 0.00 | -30.56m | 852.38m | -- | -- | 13.44 | -- | -- | -0.1167 | -0.1167 | 0.00 | 0.2017 | 0.00 | -- | -- | -- | -41.34 | -- | -45.22 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -3.57 | -- | -- | -- |
| Mesoblast Ltd | 11.60m | -113.55m | 884.05m | 83.00 | -- | 0.9947 | -- | 76.19 | -0.1376 | -0.1376 | 0.0142 | 0.7792 | 0.0112 | -- | 3.71 | 139,806.70 | -10.92 | -12.66 | -11.67 | -13.92 | -190.91 | -78.09 | -978.54 | -593.91 | -- | -3.01 | 0.1934 | -- | -26.56 | -15.43 | 10.35 | -- | 5.60 | -- |
Data as of Apr 19 2024. Currency figures normalised to Mesoblast Ltd's reporting currency: Australian Dollar AUD
10.64%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 05 Apr 2024 | 31.76m | 2.78% |
| M&G Investment Management Ltd.as of 31 Aug 2023 | 27.50m | 2.41% |
| Thorney Investment Group Australia Pty Ltd.as of 22 Sep 2023 | 21.09m | 1.85% |
| Vanguard Investments Australia Ltd.as of 29 Feb 2024 | 13.40m | 1.18% |
| Independent Asset Management Pty Ltd.as of 22 Sep 2023 | 8.00m | 0.70% |
| Dimensional Fund Advisors LPas of 29 Feb 2024 | 5.18m | 0.45% |
| Novum Asset Management AGas of 29 Feb 2024 | 4.69m | 0.41% |
| DFA Australia Ltd.as of 29 Feb 2024 | 4.64m | 0.41% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 2.76m | 0.24% |
| BlackRock Asset Management North Asia Ltd.as of 31 Jan 2024 | 2.34m | 0.21% |
More ▼
Data from 22 Sep 2023 - 08 Apr 2024Source: FactSet Research Systems Inc.
